PRA Health Sciences CLINICAL DEVELOPMENT RE-IMAGINED

2. PRA Health Sciences CLINICAL DEVELOPMENT RE-IMAGINED

3. With a mission dedicated to redefining the future of clinical development, PRA Health Sciences is leading the way in transforming and disrupting both clinical development and healthcare delivery. They recognize that the drug development industry is at cross-roads and that innovative approaches are needed to bring new therapies to more patients more efficiently and cost effectively.

4. The company has been taking a patientcentered approach and incorporating the patient voice into drug development. “We are engaging patients as consumers and integrating how we connect and deliver clinical trials to patients via the technology they use in their everyday lives, such as mobile smart devices,” says Kent Thoelke, EVP and Chief Scientific Officer at PRA. “We are exploring ways to virtualize trials to make them more accessible, particularly for hard to reach populations such as rare disease patients.”

5. In one case study, a renowned pharmaceutical client required a mobile technology solution to collect safety and effectiveness data on a groundbreaking treatment for an ultra-rare disease in a global gene therapy prospective registry. The client needed a multilingual technology platform and the solution would need to evolve with changing mobile devices’ operating systems over the study’s 15-year life cycle to remain updated, functional, and accessible. PRA’s executive medical director worked with the sponsor’s clinical and data management teams to create a flexible mobile platform for patients, parents, and caregivers. Their strategic planning and teamwork resulted in timely delivery of an efficient mobile solution for enrollment, engagement, and electronic data capture (EDC) in a single, user-friendly platform.

6. One of the unique aspects of PRA is their Embedded Solution model that can embed the right talent, processes, and technology to help partners realize their goals. Another point of pride for PRA is their Center for Pediatric Clinical Development—their answer to the industry’s critical shortage of clinical research dedicated to pediatric drug discovery. The Center functions as the central repository for all of PRA’s global pediatrics knowledge and the focal point for a specialized team of pediatric experts and advisors, equipping them to navigate the complexities of pediatric studies worldwide. Alongside, PRA’s focus on Phase I-IV study management services makes them highly competitive among larger, more diversified CROs.

7. PRA’s recent acquisition of Symphony Health Solutions and Parallel 6 strengthens their role in leading the industry’s shift into an agile, data-driven, clinical research paradigm. Symphony transforms data into decisions by providing a holistic view of the impacts of payer, prescriber, and patient behavior to shape commercial performance, productivity, and profitability. Parallel 6 and PRA’s Clinical 6 platform engages and supports patients allowing them to participate in clinical trials via a virtual/connected model using a Bring Your Own Device strategy. This industry leading platform also allows all patients access to clinical trials regardless of geography or access to a physical trial site. For the road ahead, PRA is committed to continue to look for innovative ways to improve drug development and is steadfast in their patient centric approach to growth. Read More:https://www.iconsedge.com/ranking/pra-health-sciences-clinical-development-reimagined-cid-31-mid-4.html